Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Dr. Kellum co-author on COVID-19 and PMX research

<< Previous

Bullboard Posts

Next >>

Comment by davikingon Apr 19, 2021 2:57pm

125 Views

Post# 33023178

RE:Dr. Kellum co-author on COVID-19 and PMX research

Thanks, hmmmm!
I have to pause for a moment.... and try to figure out when such information (amongst many other pieces) will be used by the company to let the story be known!
Many companies would take that and run with it in a PR! We are left searching and finding to the sleuths such as yourself, to learn about the positives of EAA and PMX.
We WAIT!

<< Previous

Bullboard Posts

Next >>

Canada Nickel unveils second of seven resources planned by mid-2025